US 12,258,577 B2
Method effector cells using anti-CD127 antibodies for applications in cell therapy
Bernard Vanhove, Reze (FR); Nicolas Poirier, Treillieres (FR); Sebastien Maury, Paris (FR); Jose Cohen, Paris (FR); Caroline Pilon, Saint Maurice (FR); and Brigitte Birebent, Yebles (FR)
Assigned to Ose Immunotherapeutics, Nantes (FR); Etablissement Francais Du Sang, La Plaine St Denis (FR); and Assistance Publique—Hopitaux De Paris, Paris (FR)
Appl. No. 16/643,550
Filed by OSE IMMUNOTHERAPEUTICS, Nantes (FR); ETABLISSEMENT FRANCAIS DU SANG, La Plaine St Denis (FR); and ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, Paris (FR)
PCT Filed Aug. 29, 2018, PCT No. PCT/EP2018/073253
§ 371(c)(1), (2) Date Feb. 29, 2020,
PCT Pub. No. WO2019/043065, PCT Pub. Date Mar. 7, 2019.
Claims priority of application No. 17306109 (EP), filed on Aug. 29, 2017.
Prior Publication US 2020/0362300 A1, Nov. 19, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/00 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01)
CPC C12N 5/0087 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4621 (2023.05); A61K 39/464419 (2023.05); A61P 35/00 (2018.01); C07K 16/2866 (2013.01); C12N 5/0636 (2013.01)] 15 Claims
 
1. A method for in vitro sorting out T effector cells from a preparation of cells obtained from a biological fluid or tissue wherein the preparation of cells comprises human cells, wherein the method comprises:
a. contacting the preparation of cells with an anti-CD127 antibody specifically binding to CD127 on said T effector cells, said anti-CD127 antibody comprising the following CDRs sequences:
in a heavy chain, CDRs of a VH3 heavy chain disclosed as sequence of SEQ ID No: 2, with CDRs of VH3-CDR1, VH3-CDR2 and VH3-CDR3 comprising or consisting of sequences of SEQ ID Nos: 14, 16 and 18, respectively and,
in a light chain, CDRs of a VL3 or of a VL4 light chain disclosed as sequences of SEQ ID Nos: 4 and 6, respectively, with CDRs VL3-CDR1, VL3/4-CDR2 and VL3/4-CDR3 having the sequences of SEQ ID Nos: 20, 22 and 24 respectively, or with CDRs of VL4-CDR1, VL3/4-CDR2 and VL3/4-CDR3 comprising or consisting of the sequences of SEQ ID Nos: 26, 22 and 24 respectively;
b. selecting sorting out said T effector cells bound to said anti-CD127 antibody and recovering the cell preparation enriched in said T effector cells and depleted for at least Treg cells;
washing the anti-CD127 antibody from said T effector cells.